Welcome to our dedicated page for Perimeter Medical Imaging Ai news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on Perimeter Medical Imaging Ai stock.
Perimeter Medical Imaging AI develops real-time optical coherence tomography imaging systems and artificial-intelligence tools for cancer surgery. The company’s Claire OCT+AI device has FDA premarket approval for intraoperative breast cancer margin assessment, while its S-Series OCT platform provides ultra-high-resolution cross-sectional visualization of excised tissue.
Company news commonly covers FDA regulatory milestones, product demonstrations, commercialization activity, clinical and technology updates, operating and financial results, investor conference presentations, and capital-structure actions such as private placements, warrants, and stock-option matters.
Perimeter Medical Imaging AI (OTCQX: PYNKF) will report fourth quarter and full year 2025 results after market close on March 31, 2026 and will host a webcast and conference call at 5:00 pm ET.
The company also entered a warrant cancellation agreement with Social Capital, surrendering 14,466,667 warrants for no consideration, reducing Social Capital's partially‑diluted stake from 30% to 22.3% (non‑diluted stake remains 22.2%).
Perimeter Medical Imaging AI (OTCQX: PYNKF) received FDA premarket approval (PMA) for Claire, the first FDA‑approved AI‑enabled intraoperative imaging device for breast cancer margin assessment. Claire demonstrated 88.1% margin accuracy and a statistically significant reduction in residual cancer; a nationwide launch begins in the coming weeks.
Claire combines patented wide‑field OCT with an AI trained on >2 million OCT images, offers ~10x higher resolution at 2mm depth, has Breakthrough Device designation, and targets an estimated 300,000 annual U.S. breast‑conserving surgeries.
Perimeter Medical Imaging AI (OTCQX: PYNKF) plans to cancel up to 2,175,619 previously issued stock options and re-grant the same number as replacement options exercisable at C$0.30 per share.
The Replacement Options vest in three schedules beginning Jan 1, 2026, retain the Original Options' expiry dates, exclude directors and officers, and are subject to approval as a re-pricing by the TSX Venture Exchange.
Perimeter Medical Imaging AI (OTCQX: PYNKF) announced a systemwide agreement with Intermountain Health on Jan. 8, 2026 to enable deployment of Perimeter's S-Series OCT imaging technology for intraoperative tissue visualization.
The arrangement covers Intermountain Health locations including LDS Hospital in Salt Lake City and American Fork Hospital and permits any of Intermountain's 34 hospitals and 400 clinics across Utah, Idaho, Nevada, Colorado, Montana and Wyoming to acquire the technology. The agreement builds on a prior Development Support Agreement that provided a framework to evaluate the OCT technology and collect data to support Perimeter's AI algorithm development.
Perimeter Medical Imaging AI (OTCQX: PYNKF) closed a C$3.56 million non-brokered private placement on Dec 9, 2025, issuing 19,757,306 units at C$0.18 each.
Each unit includes one common share and one warrant exercisable at C$0.35 for 60 months. Insiders led the financing: CEO Adrian Mendes purchased 11,656,642 units and insider Schiralli purchased 1,111,111 units. The company said net proceeds will support commercialization of the S-Series, product development, working capital and the pending FDA decision on the AI-powered B-Series expected in H1 2026.
Perimeter Medical Imaging AI (OTCQX: PYNKF) announced that HCA HealthONE Rose in Colorado is the first in the state to adopt Perimeter's S-Series OCT wide-field optical coherence tomography for intraoperative tissue visualization.
The S-Series is FDA-cleared for general tissue imaging, offers cellular-level resolution optimized to 2 mm for identifying tissue microstructures, and aims to reduce repeat surgeries by providing intraoperative margin insights previously only available from pathology results that can take up to 10 days.
HCA HealthONE Rose joins Perimeter's expanding commercial footprint while the company awaits a regulatory decision on its next-generation B-Series OCT which pairs OCT with artificial intelligence.
Perimeter Medical Imaging AI (OTCQX: PYNKF) reported Q3 2025 results with continued commercial traction for the FDA-cleared S-Series and ongoing review of the B-Series PMA, which the company expects in H1 2026. Key Q3 metrics: revenue $536,000 (+157% YoY, +6% QoQ), nine-month revenue $1.6M (+88% vs 2024), operating expenses down 34% YoY and 30% QoQ, net loss $2.7M (≈42% improvement YoY), and cash $1.7M. Installed S-Series devices have imaged >3,500 patients (17% increase). The company closed a units offering raising ≈$1.6M and scheduled a conference call today at 5:00 pm ET.
Perimeter Medical Imaging AI (OTCQX:PYNKF) will report its Third Quarter 2025 financial and operating results after market close on Wednesday, November 12, 2025. Management will host a webcast and conference call the same day to discuss results and provide a corporate update.
Conference call details: Date: November 12, 2025; Time: 5:00 pm Eastern Time; Dial-in: 1-800-717-1738 (Canada/US) or 1-646-307-1865 (International). The call will be broadcast live and archived on the company website.
Perimeter Medical Imaging AI (OTCQX: PYNKF) announced participation in the American Society of Breast Surgeons' Annual Strategic Futures Forum on October 21, 2025. The invitation-only event gathers healthcare, medical, and industry leaders to discuss the future of breast surgery and the role of integrated breast care teams.
Perimeter said the two-day Forum provides an intimate setting for small-group discussions on multidisciplinary collaboration among surgeons, oncologists, radiologists, nurses, genetic counselors, advanced practice providers, and patient navigators to improve outcomes and advance care delivery.
Perimeter Medical Imaging AI (OTCQX: PYNKF / TSXV: PINK) announced that CEO Adrian Mendes will present a company update at the Planet MicroCap Showcase on Wednesday, October 22, 2025 at 12:00 p.m. ET. The presentation will cover the company’s current commercial strategy and upcoming milestones.
The event is hosted in partnership with MicroCapClub at Arcadian Loft in Toronto and includes presentations, one-on-one investor meetings, and panels. Mr. Mendes’ presentation will be available live and archived via the company website, and 1x1 investor meetings are available in person at the conference venue by registration.